CANCER IS DETECTED TOO LATE
Exact Sciences is changing the way we think about detecting and treating cancer. As a leader in cancer testing, we are committed to providing earlier answers and life-changing treatment guidance.
Exact Sciences' new ultra-comprehensive genomic profiling test for
advanced cancers interrogates both DNA+RNA, revealing variants that
DNA alone may miss.
It uncovers rare or overlooked fusion genes and transcription variants
in nearly 20K genes and detects 41% of fusions at the RNA level alone*.
Results are delivered in an easy-to-interpret report with a spotlight on
insights that matter most.
* Retrospective analysis of 1509 clinical reports, of which 1261 included both DNA and RNA profiling. OncoExTra RNA findings detected variants in 5.9% [75/1261] of samples vs 3.5% [44/1261] in DNA analysis.
Exact Sciences’ current portfolio of products primarily focuses on colorectal, breast and prostate cancers, with research and development looking at the top 15 deadliest cancers, including multi-cancer testing.
Our vision is to eradicate cancer and the suffering it causes through tests that detect it earlier and provide guidance for successful treatment.
Our teams use their scientific expertise to continuously innovate.
Exact Sciences Laboratories are dedicated to delivering the most accurate test results to support informed decision making.